Neko Health has raised $700 million to expand its AI body scans in the United States, starting with a clinic in New York. The company’s preventive screening service combines medical imaging, blood tests, proprietary sensors, and clinician review.
The Series C round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Existing investors Atomico, General Catalyst, and Lakestar participated, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD.
David Ofer of O.G. Venture Partners will join Neko’s board, subject to regulatory approval.
The latest round brings Neko’s disclosed funding since 2023 to more than $1 billion. The company raised $65 million in a Series A round in 2023 and another $260 million in January 2025.
The round also included investments from Meta chief executive Mark Zuckerberg and Priscilla Chan, former tennis player Maria Sharapova, musician will.i.am, and former footballer Thierry Henry. Existing individual investors include Reddit co-founder Alexis Ohanian and actor Zoë Saldaña.
How Neko Health’s AI body scans work
Neko operates clinics that combine full-body scans, blood tests, artificial intelligence, and custom-built medical equipment. The service screens customers for potential signs of conditions including skin cancer, cardiovascular disease, and diabetes.
The company describes the service as a 60-minute, non-invasive, and radiation-free health assessment. It uses proprietary sensors and blood analysis to examine skin conditions, blood abnormalities, pre-diabetes indicators, and risk factors associated with metabolic syndrome, stroke, and heart attack.
The scan also includes an electrocardiogram, arterial measurements, body-composition analysis, and more than 2,000 high-resolution images used to map a customer’s skin. Blood samples are processed at the clinic, allowing the results to be reviewed during the same visit.
Results are discussed during an in-person consultation with a medical professional.
Many of the measurements, including blood pressure, blood glucose, cholesterol, electrocardiogram data, and skin assessments, are already available through conventional healthcare services. Neko’s model combines them with proprietary imaging, automated data collection, on-site blood processing, and a clinician consultation in one appointment.
The company’s public clinical materials reviewed for this article do not include a comparative study showing whether this combined approach improves clinical outcomes or cost-effectiveness compared with established preventive-care pathways.
Neko said the funding will support the opening of clinics in New York and other US cities. It has not identified the additional locations or provided a detailed expansion schedule.
A waitlist for the New York clinic is open on the company’s website. Neko has not disclosed how much its US scans will cost.
The company currently operates eight clinics across the UK and Sweden, including two in Stockholm, one each in Manchester and Birmingham, and four in London: Marylebone, Spitalfields, Covent Garden, and Victoria.
A scan costs £299 in the UK and 2,750 Swedish kronor in Sweden, equivalent to about $400 and $285.
Neko said it has completed 100,000 scans since launching its service in 2023. More than 350,000 people have registered for a scan or joined its waitlists.
According to the company, 75% of customers book and prepay for another scan at the end of their appointment.
The repeat-booking model allows clinicians to compare measurements and skin images over time. Public information reviewed for this article does not include evidence establishing whether annual screening is the appropriate interval for every age or risk group.
Founded in 2018 by Spotify co-founder Daniel Ek and chief executive Hjalmar Nilsonne, Neko operated largely outside public view until launching its service in 2023.
Nilsonne said part of the new capital will fund further research and development into preventive screening technology.
Neko recently added body-composition measurements and clinician reviews of wearable-device data across its clinics. It has also introduced updated versions of its Derma, Echo, and Spectrum medical devices, which collect information relating to skin, heart function, and circulation.
The company said the newer equipment captures a larger volume of health data and automates more parts of the scanning process. It plans to deploy the devices across its clinics in the coming months.
The clinic-based model requires proprietary equipment, blood-processing capacity, medical personnel, and specialist review for some findings. Neko said its seven-room Covent Garden clinic was designed to support tens of thousands of scans annually, but it has not disclosed capacity or staffing figures for its planned US locations.
US regulation and access
FDA records show that two of Neko’s internally developed devices received clearance through the agency’s 510(k) pathway in May 2026. Derma-2 was cleared as an adjunctive telethermographic system, while Spectrum-2 was cleared as a tissue-saturation oximeter used in cardiovascular measurements.
The clearances apply to the specified devices and their intended uses, rather than to the complete Neko Health Scan as a single FDA-approved screening service.
Neko describes its US clinics as preventive health and wellness providers rather than full-service medical practices. Its privacy notice advises customers to continue seeing their existing clinicians for diagnoses and treatment, including for conditions identified through a Neko scan.
The company says specialist clinicians, including dermatologists and cardiologists, review findings that require further examination. Follow-up appointments, referral letters, and introductions to outside specialists are included when recommended by a Neko clinician.
Neko’s US clinics do not currently participate in health insurance plans, and the company says most of its services are not covered by a payer. Customers are therefore expected to pay directly for the initial assessment.
The company has not disclosed what customers would pay for diagnostic tests or treatment delivered by external healthcare providers. It has also not announced its US price or whether employers, insurers, or other organisations will subsidise access to the service.
Questions over clinical evidence
Publicly available information reviewed for this article does not include a completed peer-reviewed study validating the full screening service. A study registered on ClinicalTrials.gov is evaluating the suitability of Neko’s multimodal skin-imaging technology for screening and diagnostic-support applications, including skin cancer and Raynaud’s phenomenon.
The trial remains an ongoing evaluation and does not establish the clinical performance of the complete Neko Health Scan.
Neko’s public materials reviewed for this article do not disclose how often its scans produce false-positive findings, how many customers undergo additional procedures, or how many flagged abnormalities are later considered clinically unimportant.
The company’s US privacy notice identifies an AI dictation system used to summarise medical records, questionnaires, scan data, and clinical conversations, and to draft reports. Neko says clinicians review reports produced using the system.
Public information does not provide a complete breakdown of which scan measurements or classifications rely on AI, conventional software, or direct clinical assessment. It also does not state that AI independently diagnoses the conditions covered by the service.
The FDA clearances for individual devices do not establish the performance of every algorithm used to combine or interpret the resulting data. Public materials reviewed for this article do not include detailed real-world performance figures for each AI system used in the screening process.
Neko’s reported health-outcome data is based on 1,469 customers who completed a second scan approximately one year after their first. The company said the group recorded improvements in blood pressure, cholesterol, and blood sugar, while body weight remained broadly stable.
The scans in the analysis were conducted at Neko’s Stockholm clinics. The company divided the results into a general group, a healthy group, and groups covering customers with hypertension, pre-diabetes, or diabetes.
Neko said the analysis was not a scientific study and did not include a control group. Customers could have started treatment or changed their behaviour between appointments, so the figures do not establish that the scans caused the reported improvements.
The analysis only covered customers who returned for a second privately purchased scan. Neko did not publish demographic information showing how that group compares with its wider customer base or the general population.
The company did not disclose its valuation following the latest round. The Financial Times, citing unnamed sources, reported that Neko is now valued at about $7 billion.
(Photo by Wonderlane)